150 filings
Page 5 of 8
DEFA14A
oahj3
29 Apr 21
Additional proxy soliciting materials
9:04am
8-K
fpvbb tc2
24 Mar 21
Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development
4:30pm
SEC STAFF
jd57cgn8o86tb
22 Mar 21
SEC staff action: Order
12:00am
S-8
fjo4034lew
4 Mar 21
Registration of securities for employees
7:21am
8-K
7m6zed
4 Mar 21
Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
7:05am
SEC STAFF
z53y5rdd20gtg85kbtt
22 Feb 21
SEC staff action: Order
12:00am
8-K
lc0yvf bkgy4n
20 Jan 21
Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock
4:05pm
424B5
huln lv6z
20 Jan 21
Prospectus supplement for primary offering
4:02pm
424B5
wkdryj
19 Jan 21
Prospectus supplement for primary offering
4:12pm
8-K
22bmnxq zd77su0q0
19 Jan 21
Results of Operations and Financial Condition
4:05pm
8-K
lrq5bshcf2fr t1k0
10 Nov 20
Fulcrum Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results
7:05am
EFFECT
ndb imvnr
18 Aug 20
Notice of effectiveness
12:15am
EFFECT
yduu0n
13 Aug 20
Notice of effectiveness
12:15am
CORRESP
3kml9f6ec
13 Aug 20
Correspondence with SEC
12:00am
UPLOAD
fn2b9x13aqtj
12 Aug 20
Letter from SEC
12:00am
POS AM
hof7h5qs7ck 3n5
11 Aug 20
Prospectus update (post-effective amendment)
7:59am
S-3
4ej5oku6 81r
11 Aug 20
Shelf registration
7:58am